Ownership history in UBS Group AG · 3 quarters on record
This page tracks every 13F SEC filing in which UBS Group AG reported a position in LIMINATUS PHARMA INC. (LIMN). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | REDUCED | 19,395 | -21,131 | -52.1% | 0.00% | $12K | $0.61 |
| 2025 Q3 | ADDED | 40,526 | +9,040 | +28.7% | 0.00% | $68K | $1.67 |
| 2025 Q2 | INITIATED | 31,486 | — | — | 0.00% | $351K | $11.15 |
As of 2025 Q4 — sorted by position size